^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIF5B-MET fusion

    i
    Other names: KIF5B, Kinesin Family Member 5B, Conventional Kinesin Heavy Chain, Ubiquitous Kinesin Heavy Chain, Kinesin-1 Heavy Chain, KNS1, UKHC, KNS, Epididymis Secretory Protein Li 61, Kinesin 1 (110-120kD), Kinesin Heavy Chain, HEL-S-61, KINH, DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233; 3799
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2years
    Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. (PubMed, Eur J Cancer)
    Resistance to MET inhibition is heterogeneous with on- and off-target mechanisms occurring regardless of the initial MET aberration. Switching therapy between different types of kinase inhibitors can lead to repeated responses in cases with second-site mutations. Controlled clinical trials in this setting with larger patient numbers are needed, as evidence to date is limited to preclinical data and case series.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • KIF5B (Kinesin Family Member 5B) • PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha) • PRKAR2B (Protein Kinase CAMP-Dependent Type II Regulatory Subunit Beta)
    |
    KRAS mutation • HER-2 amplification • MET amplification • MET exon 14 mutation • KIF5B-MET fusion • MET fusion
    almost3years
    KIF5B-MET fusion variant in non-small cell lung cancer. (PubMed, Pulmonology)
    No abstract available
    Journal
    |
    KIF5B (Kinesin Family Member 5B)
    |
    KIF5B-MET fusion • MET fusion